Guowu Wu

460 total citations
14 papers, 271 citations indexed

About

Guowu Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Guowu Wu has authored 14 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Guowu Wu's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and RNA modifications and cancer (3 papers). Guowu Wu is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and RNA modifications and cancer (3 papers). Guowu Wu collaborates with scholars based in China. Guowu Wu's co-authors include Xiaofang Zou, Lilan Yi, Longhua Guo, Ping Huang, Xue Hou, Ping Huang, Likun Chen, Zhanhong Xie, Haibo Zhang and Lin Wen and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hematology & Oncology and Pharmacological Research.

In The Last Decade

Guowu Wu

11 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guowu Wu China 6 157 129 107 101 20 14 271
Konstantin Penkov United States 10 141 0.9× 225 1.7× 89 0.8× 204 2.0× 50 2.5× 24 312
Michela Palleschi Italy 9 75 0.5× 133 1.0× 75 0.7× 189 1.9× 11 0.6× 46 281
Marta Román Spain 5 168 1.1× 126 1.0× 68 0.6× 116 1.1× 7 0.3× 7 306
Mengxi Ge China 8 97 0.6× 183 1.4× 108 1.0× 144 1.4× 9 0.5× 15 281
Alan Barnicle United Kingdom 8 76 0.5× 101 0.8× 64 0.6× 136 1.3× 11 0.6× 19 212
Xiaohuan Tang China 8 236 1.5× 91 0.7× 208 1.9× 50 0.5× 33 1.6× 14 343
Cuimin Ding China 11 214 1.4× 77 0.6× 151 1.4× 66 0.7× 7 0.3× 30 313
Friederike Schlürmann France 7 84 0.5× 217 1.7× 67 0.6× 162 1.6× 10 0.5× 12 262
Jinkai Wan China 3 180 1.1× 66 0.5× 113 1.1× 54 0.5× 11 0.6× 4 278

Countries citing papers authored by Guowu Wu

Since Specialization
Citations

This map shows the geographic impact of Guowu Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guowu Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guowu Wu more than expected).

Fields of papers citing papers by Guowu Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guowu Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guowu Wu. The network helps show where Guowu Wu may publish in the future.

Co-authorship network of co-authors of Guowu Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Guowu Wu. A scholar is included among the top collaborators of Guowu Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guowu Wu. Guowu Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Chen, Huajun, Hai‐Yan Tu, Yanping Hu, et al.. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of Hematology & Oncology. 18(1). 3–3. 3 indexed citations
2.
3.
Zou, Xiaofang, Hongzheng Ren, Shuanglong Chen, et al.. (2024). PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma. Anticancer Research. 44(2). 593–604. 1 indexed citations
4.
5.
Hou, Xue, Meichen Li, Guowu Wu, et al.. (2023). Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases. JAMA Network Open. 6(2). e2255050–e2255050. 23 indexed citations
6.
Yi, Lilan, Ping Huang, Guowu Wu, et al.. (2022). Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma. Frontiers in Oncology. 12. 794293–794293.
7.
Wu, Guowu, Longhua Guo, Tanxiao Huang, et al.. (2022). The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients. Journal of Cancer Research and Clinical Oncology. 149(3). 1019–1028. 5 indexed citations
8.
9.
Guo, Longhua, et al.. (2021). Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report. OncoTargets and Therapy. Volume 14. 1989–1995.
10.
Zhang, Li, Wen‐Feng Fang, Yunpeng Yang, et al.. (2021). A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).. Journal of Clinical Oncology. 39(15_suppl). TPS9131–TPS9131. 3 indexed citations
11.
12.
Wu, Guowu, et al.. (2020). Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis. Medical Science Monitor. 26. e920432–e920432. 13 indexed citations
13.
Yi, Lilan, et al.. (2020). Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. Pharmacological Research. 161. 105144–105144. 36 indexed citations
14.
Yi, Lilan, Guowu Wu, Longhua Guo, Xiaofang Zou, & Ping Huang. (2020). Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma. Molecular Therapy — Nucleic Acids. 21. 299–314. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Konstantin Penkov Breakdown of academic impact, for papers by Michela Palleschi Breakdown of academic impact, for papers by Marta Román Breakdown of academic impact, for papers by Mengxi Ge Breakdown of academic impact, for papers by Alan Barnicle Breakdown of academic impact, for papers by Xiaohuan Tang Breakdown of academic impact, for papers by Cuimin Ding Breakdown of academic impact, for papers by Friederike Schlürmann Breakdown of academic impact, for papers by Jinkai Wan
Rankless by CCL
2026